| Page 14 | Aplastic Anemia and MDS International Foundation

Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: past, present and future

Author(s): 
Saad, A and Lamb, LS
Primary Author: 
Saad, A
Journal Title: 
Bone Marrow Transplantation
Original Publication Date: 
Sep 2017

The most common cause of post-transplant mortality in patients with hematological malignancy is relapse, followed by GvHD, infections, organ toxicity and second malignancy. Immune-mediated complications such as GvHD continue to be challenging, yet amenable to control through manipulation of the T-cell compartment of the donor graft with subsequent immunomodulation after transplant. However, risk of both relapse and infection increase concomitantly with T-cell depletion (TCD) strategies that impair immune recovery.

Bone Marrow Diseases: 

Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence

Author(s): 
Cogle CR, Reddy SR, Chang E, Papoyan E, Broder MS, McGuire M, Binder G
Primary Author: 
Cogle CR
Journal Title: 
Leuk Res
Original Publication Date: 
Aug 2017

Bone Marrow Diseases: 

Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes

Author(s): 
Nazha A, Al-Issa K, Hamilton BK, Radivoyevitch T, Gerds AT, Mukherjee S, Adema V, Zarzour A, Abuhadra N, Patel BJ, Hirsch CM, Advani A, Przychodzen B, Carraway HE, Maciejewski JP, Sekeres MA
Primary Author: 
Nazha A
Journal Title: 
Leukemia
Original Publication Date: 
Aug 2017

No absrtact available.

Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times

Author(s): 
Patel SS, Gerds AT
Primary Author: 
Patel SS
Journal Title: 
Curr Hematol Malig Rep
Original Publication Date: 
Aug 2017

Quality of life (QOL) and symptom burden are important measures captured by patient-reported outcomes (PROs). Myelodysplastic and myelodysplastic/myeloproliferative (MDS/MPN) neoplasm overlap syndromes are notable for significant morbidity and mortality, including a wide spectrum of physical and psychosocial effects. Thus, the development and application of PROs can provide meaningful information to facilitate communication and assist in follow up care. Disease-specific measures can more accurately reflect the full breadth of functional restrictions and symptoms.

Bone Marrow Diseases: 

Predictors of early mortality after rabbit antithymocyte globulin as first-line treatment in severe aplastic anemia

Author(s): 
Atta EH, Lima CBL, Dias DSP, Clé DV, Bonduel MM, Sciuccati GB, Medeiros LA, Oliveira MM, Salvino MA, Garanito MP, Blum Fonseca PB, Saad STO, Calado RT, Scheinberg P
Primary Author: 
Atta EH
Journal Title: 
Ann Hematol
Original Publication Date: 
Aug 2017

Despite being recommended as first-line immunosuppressive therapy in severe

Bone Marrow Diseases: 

Nivolumab-induced aplastic anemia: A case report and literature review

Author(s): 
Comito RR, Badu LA, Forcello N
Primary Author: 
Comito RR
Journal Title: 
J Oncol Pharm Pract
Original Publication Date: 
Aug 2017

Directed immunotherapy at the programmed cell death-1 receptor has demonstrated efficacy in non-small-cell lung cancer, metastatic melanoma, and various other malignancies. Immune checkpoint inhibitors are innovative therapies producing some impressive clinical responses with a more manageable adverse effect profile when compared to traditional

Bone Marrow Diseases: 

Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience

Author(s): 
Boddu P, Garcia-Manero G, Ravandi F, Borthakur G, Jabbour E, DiNardo C, Jain N, Daver N, Pemmaraju N, Anderlini P, Parmar S, Kc D, Akosile M, Pierce SA, Champlin R, Cortes J, Kantarjian H, Kadia T
Primary Author: 
Boddu P
Journal Title: 
Am J Hematol
Original Publication Date: 
Aug 2017

Newer treatment modalities are being investigated to improve upon historical outcomes with standard immunosuppressive therapy (IST) in

Bone Marrow Diseases: